College Of Pharmacy Faculty Research Publication Revised January, 2016 1 Table of Contents Faculty in Medicinal Chemistry . .03 Kuberan Balagurunathan………………………………………………………………………….………… 04 Robert Selliah………………………………………………………………………………………………………. 05 Amy M. Barrios………………………………………………………………………………………………………. 06 Grzegorz Bulaj…………………………………………………………………………………………………….. 07 Tom Cheatham III……………………………………………………………………………………………………. 08 Darrell Davis………………………………………………………………………………………………………... 09 Chris Ireland………………………………………………………………………………………………….……...10 Siam Oottamasathien..…………………………………………………………………………………………... 11 Glen Prestwich…….………………………………………………………………………………………….…… 13 Eric Schmidt….…………………………………………………………………………………………….………... 14 Zhenjian Lin………………………………………………………………………………………………………….. 15 Jaclyn Winter………………………………………………………………………………………………………..16 Raphael Franzini………………………………………………………………………………………………….. 17 Margo Haygood…………………………………………………………………………………………………….. 18 Shuanghu Liu………………………………………………………………………………………………………… 19 Faculty in Pharmaceutics & Pharmaceutical Chemistry . .20 You Han Bae…………………………………………………………………………………………………………… 21 Mingnan chen….…………………………………………………………………………………………………….. 22 David W. Grainger……………………………………………………………………………………………….… 23 James Herron………………………………………………………………………………………………………… 24 Sung Wan Kim………………………………………………………………………………………………………… 25 Jindrich Henry Kopecek……………………………………………………………………………………….. 26 Carol Lim………………………………………………………………………………………………………………. 27 Hamid Ghandehari…..……………………………………………………………………………………….……. 28 John Mauger….………………………………………………………………………………………………………. 29 Shawn Owen………………………………………………………………………………………………………….. 30 Jiyuan (Jane) Yang…………………………………………………………………………………………………. 31 Faculty in Pharmacology & Toxicology . 32 Mario Alburges……………………………………………………………………………………………………... 33 Louis Barrows……………………………………………………………………………………………………..… 34 Steven Bealer………………………………………………………………………………………………………... 35 Andrea Bild……………………………………………………………………………………………………………. 36 Donald Blumenthal…………………………………………………………………………………………….... 37 William Crowley………………………………………………………………………………………………….... 38 Mike Franklin………………………………………………………………………………………………………… 39 Kristen Keefe………………………………………………………………………………………………………… 40 David Moody…………………………………………………………………………………………………………... 41 Philip Moos………………………………………………………………………………………………………..…... 42 Christopher Reilly………………………………………………………………………………………………... 43 Roy M. Smeal………………………………………………………………………………………………………….. 44 Misty D. Smith…………………………………………………………………………………………………………. 45 John Veranth…………………………………………………………………………………………………………. 46 Peter West…………………………………………………………………………………………………………….. 47 Karen Wilcox…………………………………………………………………………………………………………. 48 Faculty in Pharmacotherapy . 49 Joseph Biskupiak…………………………………………………………………………………………………... 50 Diana Brixner……………………………………………………………………………………………………….. 51 Barbara Crouch…………………………………………………………………………………………………… 52 Scott DuVall………………………………………………………………………………………………………… 53 Karen Gunning……………………………………………………………………………………………………… 54 Joanne LaFleur……………………………………………………………………………………………………. 55 Carrie McAdam-Marx……………………………………………………………………………………………. 56 Mark Munger………………………………………………………………………………………………………… 57 Nancy Nickman……………………………………………………………………………………………………… 58 Heather Nyman……………………………………………………………………………………………………… 59 Gary Oderda………………………………………………………………………………………………………….. 60 Lynda Oderda………………………………………………………………………………………………………... 61 Patricia Orlando…………………………………………………………………………………………………... 62 James Ruble……………………………………………………………………………………………………………. 63 Laura Shane-McWhorter…………………………………………………………………………………….... 64 David Stenehjem…………………………………………………………………………………………………….. 65 Vanessa Stevens…………………………………………………………………………………………………….. 66 Linda Tyler……………………………………………………………………………………………………………… 67 David Young………………………………………………………………………………………………………….... 68 Adam Bress…………………………………………………………………………………………………………….. 69 Dan Witt…………………………………………………………………………………………………………………. 70 Holly Gurgle……………………………………………………………………………………………………….…. 71 Krystal Moorman…………………………………………………………………………………………………... 72 Alisyn Hansen………………………………………………………………………………………………………… 73 Jennifer Babin……………………………………………………………………………………………………….. 74 Hannah Fudin…………………………………………………………………………………………………………. 75 Skye McKennon……………………………………………………………………………………………………… 76 2 FACULTY IN MEDICINAL CHEMISTRY 3 Kuberan (Kuby) Balagurunathan Professor of Medicinal Chemistry Email: [email protected] Website: http://www.bioscience.utah.edu/bc/bcFaculty/balagurunathan/balagurunatha.html Education & Training: M.S., 1994, Indian Institute of Technology, Madras Ph.D., 2000, University of Iowa Post-Doctoral Training, 2001-2004, MIT Research Interests: In the post-genomics era, it is now accepted that complex glycoconjugates such as proteoglycan regulate numerous patho-physiological processes in all living species. They carry enormous structural information in terms of sulfation, epimerization, domain organization, chain length, number of chains and type of chains along with their core proteins. Production of proteoglycans with such high complexity occurs in template- independent fashion seamlessly, yet our understanding of their biosynthesis, structures and functions is somewhat incomplete and imperfect. We are developing a wide variety of chemical biology tools to define the biosynthetic pathways of heparan sulfate and related glycosaminoglycans (GAG) such as chondroitin sulfate and dermatan sulfate. We synthesize heparin and heparan sulfate structures with a dozen recombinant enzymes to define the structural basis for the interactions of growth factors and Heparan sulfates and the subsequent biological actions. We recently found that a library of click- xylosides produce distinct GAG chains in cellular systems and proposed a GAGOSOME model for the dynamic regulation of combinatorial GAG biosynthesis. These molecular tools are currently used in the lab to define the snap shots of biosynthetic events and signaling events that are associated with development and diseases with a final goal to advance the study of heparanomics. 4 Robert Selliah Adjunct Faculty Email: [email protected] Education & Training: B.S Special Honors in Chemistry Ph.D. Synthetic Organic Chemistry from University of Texas at Austin Research Interests: Dr. Selliah has more than 18 years of experience in technology, leadership, and management in drug discovery, medicinal chemistry, and preclinical development in the United States and the global pharmaceutical and biotech sector. He was most recently vice president of Medicinal Chemistry at SAI Advantium Pharma in India, where he led a group of over 200 scientists. Dr. Selliah is a co-inventor of two clinical development candidates—PRLX93936 (oncology, Prolexys) and AL12182 (glaucoma, Alcon)—and several preclinical candidates, and he contributed to the discovery and development of Travatan®, a marketed prostaglandin drug for glaucoma. He currently serves as a consultant in drug discovery, medicinal chemistry, and project management to early- stage biotech companies in the U.S. 5 Amy M. Barrios Associate Professor of Medicinal Chemistry Email: [email protected] Website: http://www.bioscience.utah.edu/bc/bcFaculty/barrios/barrios.html Education and Training: B.S., 1989, University of Utah, Salt Lake City, UT, Chemistry Ph.D., 2000, Massachusetts Institute of Technology, Cambridge, MA, Inorganic Chemistry Research Interests: Our laboratory has focused on developing chemical tools that can be used to solve important biological problems. In particular, our work has focused on developing novel approaches to assaying enzymatic activity. For example, we have developed a fluorogenic, phosphotyrosine mimetic amino acid that can be used to develop peptide- based substrates for assaying Protein Tyrosine Phosphatase (PTP) activity both in vitro and also in living cells. We have also developed a novel fluorogenic assay for enzymes that produce hydrogen sulfide, including Cystathionine beta-Synthase (CBS). We have conducted a series of high-throughput screens to identify novel inhibitors of both the PTPs and CBS and have used the combination of tools developed in our lab to develop greater insight into the biological activity of these diverse but critically important enzyme families. Our work on understanding tyrosine phosphorylation and hydrogen sulfide mediated cellular signaling continues as we add a new area of research to the laboratory: developing a panel of enzyme activity assays for use in profiling the functional capabilities of a complex microbiome. 6 Grzegorz (Greg) Bulaj Associate Professor of Medicinal Chemistry Email: [email protected] Website: http://pharmacy.utah.edu/medchem/faculty/Bulaj_G.htm Education and Training: Ph.D., 1993, University of Wroclaw, Poland M.Sc., 1989, Biochemistry, University of Wroclaw Research Interests: The long-term goal of our research is to develop a drug-device combination therapy which targets a chronic disease at both molecular and behavioral levels. Two reasons for advancing such strategy are: (1) approximately half of chronically-ill patients do not take medication as prescribed, and (2) mobile medical applications and medical devices provide tools for behavioral interventions and disease management. The integrated molecular-behavioral targeting of a chronic disease opens new opportunities to improve medication adherence and pharmacotherapy outcomes. Our current research is focused on medical devices to be combined with appropriate drug-based therapies for treating cancer or epilepsy. We have been developing an exercise-empowerment